Literature DB >> 20425262

New evidence extending the benefit of treating LDL-C beyond the current guidelines.

Michael Clearfield1.   

Abstract

Year:  2010        PMID： 20425262     DOI： 10.1007/s11883-009-0081-z

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  18 in total

1.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors:  P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

2.  The editor's roundtable: the JUPITER trial--initial results and clinical implications.

Authors:  Paul M Ridker; Vincent E Friedewald; Michael H Davidson; James T Willerson; William C Roberts
Journal:  Am J Cardiol       Date:  2009-05-15       Impact factor: 2.778

3.  Elevated C-reactive protein in atherosclerosis--chicken or egg?

Authors:  Heribert Schunkert; Nilesh J Samani
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

4.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

Review 5.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

6.  Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco Ah Fonseca; Jacques Genest; Antonio M Gotto; John Jp Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G Macfadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

7.  Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis.

Authors:  Scott Kinlay
Journal:  J Am Coll Cardiol       Date:  2007-05-04       Impact factor: 24.094

8.  Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort).

Authors:  William B Kannel; Ramachandran S Vasan; Michelle J Keyes; Lisa M Sullivan; Sander J Robins
Journal:  Am J Cardiol       Date:  2008-02-15       Impact factor: 2.778

9.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

10.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.

Authors:  P M Kearney; L Blackwell; R Collins; A Keech; J Simes; R Peto; J Armitage; C Baigent
Journal:  Lancet       Date:  2008-01-12       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.